Blog Read the latest perspectives from our team of subject matter experts and others Why Clinical Development Decisions Need to Be ConnectedA clinical study moves forward through a series of connected decisions. Yet the context behind those decisions does not always move with them. Portfolio priorities inform the study design, which… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Defacto Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology Policy and Regulation Drug DevelopmentWhy Clinical Development Decisions Need to Be ConnectedA clinical study moves forward through a series of connected decisions. Yet the context behind those decisions does not always move with them. Portfolio priorities inform the study design, which… Continue reading → Read the articleyes Provider DataThe Eroding Value of Provider Directory Phone Call AuditsThe views and opinions expressed are those of the author(s) and do not necessarily reflect the views or positions of H1. Imagine a health plan’s AI voice agent calling a… Continue reading → Read the articleno Drug DevelopmentBelgium Drug Development SpotlightBelgium represents approximately 2.6% of the EU population, yet it ranked second among the European countries analyzed for clinical trial authorizations per capita over the past five years, according to… Continue reading → Read the articleno Artificial IntelligenceDrug DevelopmentBeyond the AI Pilot: Building the Foundation for Clinical Trial ImpactAs we witness AI solutions being deployed into clinical trials and in drug development in general, an important question remains: is it actually making a difference? That question was at… Continue reading → Read the articleno Provider DataDefacto Health Joins H1When we started Defacto Health, we set out to solve a single problem: the industry had no way of knowing which providers were in which payers’ networks. At best, providers… Continue reading → Read the articleno Artificial IntelligenceDrug DevelopmentH1 Announces Strategic Partnership with Mirai AdvisorsStephanie Bova, Director, Mirai Advisors We’re pleased to highlight our strategic partnership with Stephanie Bova and Mirai Advisors. Under Stephanie’s leadership, Mirai Advisors partners with senior healthcare leaders to deploy… Continue reading → Read the articleno1234›»